Prevention and nondialytic treatment of acute renal failure

Current Opinion in Critical Care

Volumn 9, Issue 6, 2003, Pages 481-490

  Lameire, Norbert H ^a   De Vriese, An S ^b   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Sint Jan General Hospital   (Belgium)

Author keywords

Acute renal failure; Pathophysiology; Pharmacologic measures; Prophylactic measures

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ACETYLCYSTEINE; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPHYLLINE; AMPHOTERICIN B; ARGIPRESSIN; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; DILTIAZEM; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ETACRYNIC ACID; FENOLDOPAM; FUROSEMIDE; LOOP DIURETIC AGENT; MANNITOL; METHOTREXATE; NORADRENALIN; PROSTAGLANDIN E1; RASBURICASE; SULFONAMIDE; THEOPHYLLINE; UNINDEXED DRUG; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; CROSSOVER PROCEDURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HUMAN; HYDRATION; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NEPHROTOXICITY; OTOTOXICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SEPTIC SHOCK; VASOCONSTRICTION; VASODILATATION;

ACETYLCYSTEINE; CALCIUM CHANNEL BLOCKERS; CRUSH SYNDROME; DIURETICS; FLUID THERAPY; FREE RADICAL SCAVENGERS; GROWTH SUBSTANCES; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY TUBULAR NECROSIS, ACUTE; MANNITOL; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0344254673     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200312000-00004     Document Type: Review

References (107)

1. Molitoris BA: Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol 2003, 14:265-267. This is an excellent review of new insights into the pathophysiology and therapy of ischemic ARF.
2. Conger JD: Vascular alterations in acute renal failure: roles in initiation and maintenance. In Acute Renal Failure: A Companion to Brenner & Rector's The Kidney. Edited by Molitoris BA, Finn WF. Philadelphia: WB Saunders; 2001:13-29.
3. Sutton TA, Mang HE, Campos SB, et al.: Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003, 285:F191-F198. This is a beautiful study on the mechanisms of endothelial cell damage in the acute ischemic kidney.
4. Sutton TA, Molitoris BA: Mechanisms of cellular injury in ischemic acute renal failure. Semin Nephrol 1998, 18:490-497.
5. Sheridan AM, Bonventre JV: Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000, 9:427-434.
6. Sheridan AM, Bonventre JV: Pathophysiology of ischemic acute renal failure. Contrib Nephrol 2001, 132:7-21.
7. Blantz RC: Pathophysiology of pre-renal azotemia. Kidney Int 1998, 53:512-523.
8. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002, 3233-3242.
9. Stirling C, Houston J, Robertson S, et al.: Diarrhoea, vomiting and ACE inhibitors: an important cause of acute renal failure. J Hum Hypertens 2003, 17:419-423.
10. Ahmed A: Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc 2002, 50:1297-1300.
11. Maier KG, Roman RJ: Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 2001, 10:81-87.
12. Racusen LC: The morphologic basis of acute renal failure. In Acute Renal Failure: A Companion to Brenner & Rector's The Kidney. Edited by Molitoris BA, Finn WF. Philadelphia: WB Saunders; 2001:1-12.
13. Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996, 334:1448-1460.
14. Heyman SN, Lieberthal W, Rogiers P, et al.: Animal models of acute tubular necrosis. Curr Opin Crit Care 2002, 8:526-534. This is a discussion of the many caveats of most animal models for the interpretation of human ARF.
15. Myers BD, Chui F, Hilberman M, et al.: Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol 1979, 237:F319-F325.
16. Ramaswamy D, Corrigan G, Polhemus C, et al.: Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Physiol Renal Physiol 2002, 282:F271-F280.
17. Scandling JD, Myers BD: Pathophysiology of reduced glomerular filtration rate in delayed graft function. Curr Opin Nephrol Hypertens 1997, 6:405-409.
18. Lieberthal W, Koh JS, Levine JS: Necrosis and apoptosis in acute renal failure. Semin Nephrol 1998, 18:505-518.
19. Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367.
20. Van den Berghe G, Wouters PJ, Bouillon R, et al.: Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003, 31:359-366.
21. Ragaller MJ, Theilen H, Koch T: Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 2001, 12(suppl 1 7):S33-S39.
22. Waikar SS, Chertow GM: Crystalloids versus colloids for resuscitation in shock. Curr Opin Nephrol Hypertens 2000, 9:501-504.
23. De Vriese AS: Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol 2003, 14:792-805. This is the most recent excellent summary of all the mechanisms and therapeutic interventions in sepsis and septic shock.
24. Gattinoni L, Brazzi L, Pelosi P, et al.: A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995, 333:1025-1032.
25. Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
26. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998, 316:961-964.
27. Choi PT, Yip G, Quinonez LG, et al.: Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999, 27:200-210.
28. Schortgen F, Lacherade JC, Bruneel F, et al.: Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001, 357:911-916.
29. Cittanova ML, Leblanc I, Legendre C, et al.: Effect of hydroxyethyl starch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996, 348:1620-1622.
30. Boldt J, Brenner T, Lehmann A, et al.: Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 2003, 29:763-769. This paper deals with the different forms of fluid therapy in critically ill patients. There are excellent discussions and it is very relevant for the intensivist.
31. Boldt J, Muller M, Mentges D, et al.: Volume therapy in the critically ill: is there a difference? Intensive Care Med 1998, 24:28-36.
32. Lameire N, Verbeke M, Vanholder R: Prevention of clinical acute tubular necrosis with drug therapy. Nephrol Dial Transplant 1995, 10:1992-2000.
33. Costa S, Nucci M: Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 2001, 7:379-383.
34. Solomon R, Werner C, Mann D, et al.: Effects of saline, mannitol and furosemide on acute decreases in renal function by radiocontrast agents. N Engl J Med 1994, 331:1414-1416.
35. Lameire N: Acute tumour lysis syndrome and the kidney (editorial). Neth J Med 1994, 45:193-197.
36. Pui CH: Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002, 3:433-452.
37. Ribeiro RC, Pui CH: Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. Clin Lymphoma 2003, 3:225-232. This article presents a new approach in the treatment of tumor lysis syndrome.
38. Vanholder R, Sever MS, Erek E, et al.: Rhabdomyolysis. J Am Soc Nephrol 2000, 11:1553-1561.
39. Carmichael P, Carmichael AR: Acute renal failure in the surgical setting. Aust N Z J Surg 2003, 73:144-153.
40. Schetz M: Vasopressors and the kidney. Blood Purif 2002, 20:243-251. This is an excellent summary of the use of vasopressors in hypotensive critically ill patients. Do not be afraid of norepinephrine!
41. Martin C, Viviand X, Leone M, et al.: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000, 28:2758-2765.
42. Duke GJ, Briedis JH, Weaver RA; Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994, 22:1919-1925.
43. Takala J, Meier-Hellmann A, Eddleston J, et al.: Effect of dopexamine on outcome after major abdominal surgery: a prospective, randomized, controlled multicenter study. European Multicenter Study Group on Dopexamine in Major Abdominal Surgery. Crit Care Med 2000, 28:3417-3423.
44. Dehne MG, Klein TF, Muhling J, et al.: Impairment of renal function after cardiopulmonary bypass is not influenced by dopexamine. Ren Fail 2001, 23:217-230.
45. Ralph CJ, Tanser SJ, Macnaughton PD, et al.: A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. Intensive Care Med 2002, 28:884-890.
46. Tsuneyoshi I, Yamada H, Kakihana Y, et al.: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilator/septic shock. Crit Care Med 2001, 29:487-493.
47. Patel BM, Chittock DR, Russell JA, et al.: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-582.
48. Krismer AC, Wenzel V, Mayr VD, et al.: Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: current experience and future perspectives. Curr Opin Crit Care 2001, 7:157-169.
49. Conger JD: Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995, 26:565-576.
50. Lameire N, Vanholder R: Drug therapy of acute renal failure. Drugs 2000, 3:1206-1216.
51. Dishart MK, Kellum JA: An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. Drugs 2000, 59:79-91.
52. Wang A, Holcslaw T, Bashore TM, et al.: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000, 57:1675-1680.
53. Erley CM, Duda SH, Schlepckow S, et al.: Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994, 45:1425-1431.
54. Erley CM: Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999, 14:1064-1066.
55. Erley CM, Duda SH, Rehfuss D, et al.; Prevention of radiocontrast media induced nephropathy in patients with preexisting renal insufficiency by hydration in combination with the adenosine antagonist aminophylline. Nephrol Dial Transplant 1999, 14:1146-1149.
56. Abizaid AS, Clark CE, Mintz GS, et al.: Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999, 83:260-263.
57. Koch JA, Plum J, Grabensee B, et al.: Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 2000, 15:43-49.
58. Sketch MH Jr, Whelton A, Schollmayer E, et al.: Prevention of contrast mediainduced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 2001, 8:155-162.
59. Gilbert TB, Hasnain JU, Flinn WR, et al.: Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. J Cardiovasc Pharmacol Ther 2001, 6:31-36.
60. Chu VL, Cheng JW: Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother 2001, 35:1278-1282.
61. Lepor NE: A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Rev Cardiovasc Med 2003, 4(suppl 1):S15-S20.
62. Sheinbaum R, Ignacio C, Safi HJ, et al.: Contemporary strategies to preserve renal function during cardiac and vascular surgery. Rev Cardiovasc Med 2003, 4(suppl 1):S21-S28.
63. Seri I, Kone BC, Gullans SR, et al.: Locally formed dopamine inhibits Na+-K+-ATPase activity in rat renal cortical tubule cells. Am J Physiol 1988, 255:F666-F673.
64. Heyman SN, Kaminski N, Brezis M: Dopamine increases renal medullary blood flow without improving regional hypoxia. Exp Nephrol 1995, 3:331-337.
65. Denton MD, Chertow GM, Brady HR: Renal-dose dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996, 50:4-14.
66. Kellum JA, Decker M: Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001, 29:1526-1531.
67. Weisberg LS, Kurnik PB, Kurnik BR: Risk of radio-contrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994, 45:259-265.
68. Stevens MA, McCullough PA, Tobin KJ, et al.: A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy-results of the PRINCE study. J Am Coll Cardiol 1999, 33:403-411.
69. Lassnigg A, Donner E, Grubhofer G, et al.: Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000, 11:97-104.
70. Chertow GM, Sayegh MH, Allgren RL, et al.: Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 1996, 101:49-53.
71. Bellomo R, Chapman M, Finfer S, et al.: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000, 356:2139-2143.
72. Segal JM, Phang PT, Walley KR: Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 1992, 73:1159-1164.
73. Van den Berghe G, De Zegher F: Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996, 24:1580-1590.
74. Michael U, Lee SM: The role of calcium antagonists in nephrotoxic models of renal failure. In Calcium Antagonists and The Kidney. Edited by Epstein M, Loutzenheimer R. Philadelphia: Hanley, Belfus; 1990:187-201.
75. Neumayer HH, Kunzendorf U, Schreiber M: Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992, 41:S8-S93.
76. Wagner K, Henkel M, Heinemeyer G, et al.: Interaction of calcium blockers and cyclosporine. Transplant Proc 1988, 20:561-568.
77. Puig JM, Lloveras J, Oliveras A, et al.: Usefulness of diltiazem in reducing the incidence of acute tubular necrosis in Euro-Collins preserved cadaveric renal grafts. Transplant Proc 1991, 23:2368-2369.
78. Ladefoged SD, Andersen CB: Calcium channel blockers in kidney transplantation. Clin Transplant 1994, 8:128-133.
79. Lumlertgul D, Wongmekiat O, Sirivanichai C, et al.: Intrarenal infusion of gallopamil in acute renal failure. A preliminary report. Drugs 1991, 42(suppl 1):44-50.
80. Piper SN, Kumle B, Maleck WH, et al.: Diltiazem may preserve renal tubular integrity after cardiac surgery. Can J Anaesth 2003, 50:285-292.
81. Kellum JA: Use of diuretics in the acute care setting. Kidney Int Suppl 1998, 66:S67-S70.
82. Gubern JM, Sancho JJ, Simo J, et al.: A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988, 103:39-44.
83. Sitges-Serra A, Carulla X, Piera C, et al.: Body water compartments in patients with obstructive jaundice. Br J Surg 1992, 79:533-536.
84. Van Valenberg PLJ, Hoitsma A, Tiggeler RWGL, et al.: Mannitol as an indispensable constituent of an intravenous hydration protocol for the prevention of acute renal failure after cadaveric renal transplantation. Transplantation 1987, 44:784-788.
85. Abassi ZA, Hoffman A, Better OS: Acute renal failure complicating muscle crush injury. Semin Nephrol 1998, 18:558-565.
86. Better OS, Rubinstein I, Reis DN: Muscle crush compartment syndrome: fulminant local edema with threatening systemic effects. Kidney Int 2003, 63:1155-1157. This is a short review of the beneficial effects of mannitol in the prevention of the muscle compartment syndrome in rhabdomyolysis.
87. Solomon R, Werner C, Mann D, et al.: Effects of saline, mannitol and furosemide to prevent acute decreases in renal function by radiocontrast agents. N Engl J Med 1994, 331:1414-1416.
88. Dorman HR, Sondheimer JH, Chadnapaphomhai P: Mannitol-induced acute renal failure. Medicine (Baltimore) 1990, 69:153-159.
89. Anderson RJ, Linas SL, Berns AS, et al.: Nonoliguric acute renal failure. N Engl J Med 1977, 296:1134-1138.
90. Klinge J: Intermittent administration of furosemide or continuous infusion in critically ill infants and children: does it make a difference? Intensive Care Med 2001, 27:623-624.
91. Shilliday IR, Quinn KJ, Allison ME: Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 1997, 12:2592-2596.
92. Lieberthal W, Levinsky NG: Treatment of acute tubular necrosis. Semin Nephrol 1990, 10:571-583.
93. Mehta RL, Chertow GM: Diuretics in critically ill patients with acute renal failure. JAMA 2003, 289:1379-1381.
94. Mehta RL, Pascual MT, Soroko S, et al.: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288:2547-2553. This excellent study had somewhat surprising results, illustrating the negative effects of loop diuretics in critically ill patients.
95. Lameire N, Vanholder R, Van Biesen W: Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002, 288:2599-2601.
96. Safirstein R, Andrade L, Vieira JM: Acetylcysteine and nephrotoxic effects of radiographic contrast agents - a new use for an old drug. N Engl J Med 2000, 343:210-212.
97. Tepel M, van der Giet M, Schwarzfeld C, et al.: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
98. Brophy DF: Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. Ann Pharmacother 2002, 36:1466-1470.
99. Boccalandro F, Amhad M, Smalling RW, et al.: Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003, 58:336-341.
100. Briguori C, Manganelli F, Scarpato P, et al.: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002, 40:298-303.
101. Durham JD, Caputo C, Dokko J, et al.: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002, 62:2202-2207.
102. Hackam D, Anand SS: Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. Vasc Med 2002, 7:337-338.
103. Shyu KG, Cheng JJ, Kuan P: Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002, 40:1383-1388.
104. Tadros GM, Mouhayar EN, Akinwande AO, et al.: Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol 2003, 15:311-314.
105. Hammerman MR: Growth factors and apoptosis in acute renal injury. Curr Opin Nephrol Hypertens 1998, 7:419-424.
106. Hladunewich MA, Corrigan G, Derby GC, et al.: A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF. Kidney Int 2003, 64:593-602. This is the most recent study on the absence of beneficial effects of insulinlike growth factor-1 in the prevention of posttransplant ARF.
107. Acker CG, Singh AR, Flick RP, et al.: A trial of thyroxine in acute renal failure. Kidney Int 2000, 57:293-298.